TyK2抑制剂deucravacitinib治疗系统性红斑狼疮的研究进展 点击下载
| 论文标题： | TyK2抑制剂deucravacitinib治疗系统性红斑狼疮的研究进展 |
| 英文标题： | |
| 中文摘要： | deucravacitinib是一种选择性酪氨酸激酶2抑制剂，对于各种免疫系统疾病均显示出一定的治疗潜力，其用于系统性红斑狼疮（SLE）目前还处在临床试验阶段。deucravacitinib口服给药易吸收，并可在24h内引起药效学效应。与安慰剂比较，治疗第32周时，deucravacitinib组患者符合SLE反应指数4的比例更高，且在英国狼疮评估小组综合狼疮评估、皮肤红斑狼疮疾病面积和严重程度指数50、狼疮低疾病活动状态和活动、肿胀及压痛关节计数方面的反应率也更高。安全性方面，deucravacitinib组皮疹、痤疮等不良事件发生率较高，但仍需进一步观察。目前，已有更多研究正在对deucravacitinib治疗SLE的有效性和安全性进行评估，期待更多数据验证deucravacitinib的治疗潜力。 |
| 英文摘要： | Deucravacitinib is a selective tyrosine kinase 2 inhibitor. It has shown certain therapeutic potential for various immune system diseases， and its use in systemic lupus erythematosus （SLE） is currently in the clinical trial stage. Deucavacitinib is easily absorbed by oral administration and can cause pharmacological effects within 24 hours. Compared with placebo， after 32 weeks of treatment， patients in the deucravacitinib group who meet the SLE response index 4 have a higher proportion， and a higher response rate in the British Isles Lupus Assessment Group’s comprehensive lupus assessment， cutaneous lupus erythematosus disease area and severity index of 50， low disease activity status， and activity， swelling， and tenderness joint counts. In terms of safety， the incidence of adverse events such as rash and acne is higher in the deucravacitinib group than placebo group， but further observation was still needed. At present， more studies are evaluating the cost-effectiveness and safety of deucravatinib in the treatment of SLE， with the expectation of more data validation of deucravatinib’s therapeutic potential. |
| 期刊： | 2023年第34卷第12期 |
| 作者： | 赵玥；钟雪；杨照 |
| 英文作者： | ZHAO Yue，ZHONG Xue，YANG Zhao |
| 关键字： | deucravacitinib；酪氨酸激酶抑制剂；系统性红斑狼疮 |
| KEYWORDS： | deucravacitinib； tyrosine kinase inhibitor； systemic lupus erythematosus |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！